MedTech Terms
    The authoritative reference
    All terms
    RegulatoryRegulated PathwaysGlobal MarketsStartup LifecycleACNU

    Additional Condition for Nonprescription Use

    FDA's 2024 final rule creating a pathway for nonprescription drug products that rely on additional conditions (e.g., self-selection tools, drug-device combinations) to ensure safe use without a healthcare provider.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

    Definition

    An Additional Condition for Nonprescription Use (ACNU) is a labeling or implementation condition, beyond conventional Drug Facts labeling, that FDA may require for a nonprescription drug product to assure consumers can self-select and self-use the product safely. ACNUs may include digital self-assessment apps, device-mediated questionnaires, response-based vending, or other technological gating mechanisms. The final rule (Dec 2024) creates an explicit regulatory framework for products that would otherwise be unable to switch from Rx to OTC because labeling alone cannot ensure safe use.
    What the regulation says
    21 CFR Part 330 amended by the December 2024 ACNU final rule. Combination products with an ACNU device component are subject to combination product jurisdiction under 21 CFR Part 3.

    What this means in practice

    ACNU is highly relevant to drug-device combination products and digital therapeutics that act as the 'additional condition' enabling safe OTC use. Examples include app-mediated screening for hormonal contraceptives, device-confirmed glucose checks for OTC insulin pens, or AI-assisted symptom triage gating access to a Rx-to-OTC switch. Manufacturers building these conditions must meet medical device requirements (often as a SaMD) in parallel with the drug NDA/ANDA pathway.
    Common pitfalls
    • •Treating an ACNU app as marketing software, it is part of the labeling and likely a regulated medical device.
    • •Failing to integrate human factors testing of the ACNU early, FDA expects evidence the additional condition actually achieves safe self-selection.
    • •Ignoring post-market obligations, manufacturers must monitor whether the ACNU continues to function as intended in real-world use.

    Primary references

    3 sources
    Link health: 2 verified 1 bot-blocked· last checked 2026-06-20
    Federal Register·1FDA·1European Commission·1
    1. 1
      FDA ACNU Final Rule (Dec 2024)
      Verified
      Federal Registerfederalregister.gov
    2. 2
      FDA ACNU Web Page
      Bot-blocked
      FDAfda.gov
    3. 3
      European Commission - Medical Devices
      Verified
      European Commissionhealth.ec.europa.eu

    Inline markers like [1] jump to the matching reference above.